UGCG and B-cell chronic lymphocytic leukemia: Our data support the notion that UGCG inhibitors efficiently lead to an accumulation of GluCer and that they can confer benefits both alone and in combination with ibrutinib, as evidenced by the decreased viability of cell models and primary CLL patients' cells.